Quarterly ResultAug 13, 2026, 04:45 PM
Ensysce Biosciences Q2 Net Loss Widens to $2.57M; Going Concern Doubt
AI Summary
Ensysce Biosciences reported a widened net loss of $2.57 million for Q2 2026, compared to $1.73 million in Q2 2025. For the six months ended June 30, 2026, the net loss was $6.13 million, up from $3.68 million in the prior year. The company's cash and cash equivalents significantly decreased to $676,704 from $4.31 million at year-end 2025, and it explicitly stated substantial doubt about its ability to continue as a going concern. Federal grant revenue also declined, while research and development expenses increased.
Key Highlights
- Net loss for Q2 2026 widened to $(2.57) million from $(1.73) million in Q2 2025.
- Net loss for the six months ended June 30, 2026, increased to $(6.13) million from $(3.68) million.
- Cash and cash equivalents decreased to $676,704 as of June 30, 2026, from $4.31 million at year-end 2025.
- Total stockholders' equity shifted to a deficit of $(1.11) million from $2.88 million.
- Company expressed substantial doubt about its ability to continue as a going concern.
- Federal grants revenue decreased to $1.16 million in Q2 2026 from $1.37 million in Q2 2025.
- Research and development expenses rose to $2.47 million in Q2 2026 from $1.92 million.
- A second multi-year MPAR Grant provides $15.1 million in funding, with $5.3 million remaining.
- Net cash used in operating activities for H1 2026 was $(5.46) million, up from $(4.41) million.
Price Impact
More from ENSC